Scaffold-based rhBMP-2 therapy in a rat alveolar defect model: Implications for human gingivoperiosteoplasty

Phuong D. Nguyen, Clarence D. Lin, Alexander C. Allori, Jeffrey S. Schachar, John Ricci, Pierre B. Saadeh, Stephen M. Warren

Research output: Contribution to journalArticle

Abstract

Background: Primary alveolar cleft repair has a 41 to 73 percent success rate. Patients with persistent alveolar defects require secondary bone grafting. The authors investigated scaffold-based therapies designed to augment the success of alveolar repair. Methods: Critical-size, 7 × 4 × 3-mm alveolar defects were created surgically in 60 Sprague-Dawley rats. Four scaffold treatment arms were tested: absorbable collagen sponge, absorbable collagen sponge plus recombinant human bone morphogenetic protein-2 (rhBMP-2), hydroxyapatite-tricalcium phosphate, hydroxyapatite-tricalcium phosphate plus rhBMP-2, and no scaffold. New bone formation was assessed radiomorphometrically and histomorphometrically at 4, 8, and 12 weeks. Results: Radiomorphometrically, untreated animals formed 43 ± 6 percent, 53 ± 8 percent, and 48 ± 3 percent new bone at 4, 8, and 12 weeks, respectively. Animals treated with absorbable collagen sponge formed 50 ± 6 percent, 79 ± 9 percent, and 69 ± 7 percent new bone, respectively. Absorbable collagen sponge plus rhBMP-2-treated animals formed 49 ± 2 percent, 71 ± 6 percent, and 66 ± 7 percent new bone, respectively. Hydroxyapatite- tricalcium phosphate treatment stimulated 69 ± 12 percent, 86 ± 3 percent (p < 0.05), and 87 ± 14 percent new bone, respectively. Histomorphometry demonstrated an increase in bone formation in animals treated with hydroxyapatite-tricalcium phosphate plus rhBMP-2 (p < 0.05; 4 weeks) compared with empty scaffold. Conclusions: Radiomorphometrically, absorbable collagen sponge and hydroxyapatite-tricalcium phosphate scaffolds induced more bone formation than untreated controls. The rhBMP-2 added a small but significant histomorphometric osteogenic advantage to the hydroxyapatite- tricalcium phosphate scaffold.

Original languageEnglish (US)
Pages (from-to)1829-1839
Number of pages11
JournalPlastic and Reconstructive Surgery
Volume124
Issue number6
DOIs
StatePublished - Dec 2009

Fingerprint

Durapatite
Porifera
Collagen
Osteogenesis
Bone and Bones
Therapeutics
Bone Transplantation
Sprague Dawley Rats
recombinant human bone morphogenetic protein-2
tricalcium phosphate

ASJC Scopus subject areas

  • Surgery

Cite this

Scaffold-based rhBMP-2 therapy in a rat alveolar defect model : Implications for human gingivoperiosteoplasty. / Nguyen, Phuong D.; Lin, Clarence D.; Allori, Alexander C.; Schachar, Jeffrey S.; Ricci, John; Saadeh, Pierre B.; Warren, Stephen M.

In: Plastic and Reconstructive Surgery, Vol. 124, No. 6, 12.2009, p. 1829-1839.

Research output: Contribution to journalArticle

Nguyen, Phuong D. ; Lin, Clarence D. ; Allori, Alexander C. ; Schachar, Jeffrey S. ; Ricci, John ; Saadeh, Pierre B. ; Warren, Stephen M. / Scaffold-based rhBMP-2 therapy in a rat alveolar defect model : Implications for human gingivoperiosteoplasty. In: Plastic and Reconstructive Surgery. 2009 ; Vol. 124, No. 6. pp. 1829-1839.
@article{1af8b9f32295454c9e398eeb6632f79d,
title = "Scaffold-based rhBMP-2 therapy in a rat alveolar defect model: Implications for human gingivoperiosteoplasty",
abstract = "Background: Primary alveolar cleft repair has a 41 to 73 percent success rate. Patients with persistent alveolar defects require secondary bone grafting. The authors investigated scaffold-based therapies designed to augment the success of alveolar repair. Methods: Critical-size, 7 × 4 × 3-mm alveolar defects were created surgically in 60 Sprague-Dawley rats. Four scaffold treatment arms were tested: absorbable collagen sponge, absorbable collagen sponge plus recombinant human bone morphogenetic protein-2 (rhBMP-2), hydroxyapatite-tricalcium phosphate, hydroxyapatite-tricalcium phosphate plus rhBMP-2, and no scaffold. New bone formation was assessed radiomorphometrically and histomorphometrically at 4, 8, and 12 weeks. Results: Radiomorphometrically, untreated animals formed 43 ± 6 percent, 53 ± 8 percent, and 48 ± 3 percent new bone at 4, 8, and 12 weeks, respectively. Animals treated with absorbable collagen sponge formed 50 ± 6 percent, 79 ± 9 percent, and 69 ± 7 percent new bone, respectively. Absorbable collagen sponge plus rhBMP-2-treated animals formed 49 ± 2 percent, 71 ± 6 percent, and 66 ± 7 percent new bone, respectively. Hydroxyapatite- tricalcium phosphate treatment stimulated 69 ± 12 percent, 86 ± 3 percent (p < 0.05), and 87 ± 14 percent new bone, respectively. Histomorphometry demonstrated an increase in bone formation in animals treated with hydroxyapatite-tricalcium phosphate plus rhBMP-2 (p < 0.05; 4 weeks) compared with empty scaffold. Conclusions: Radiomorphometrically, absorbable collagen sponge and hydroxyapatite-tricalcium phosphate scaffolds induced more bone formation than untreated controls. The rhBMP-2 added a small but significant histomorphometric osteogenic advantage to the hydroxyapatite- tricalcium phosphate scaffold.",
author = "Nguyen, {Phuong D.} and Lin, {Clarence D.} and Allori, {Alexander C.} and Schachar, {Jeffrey S.} and John Ricci and Saadeh, {Pierre B.} and Warren, {Stephen M.}",
year = "2009",
month = "12",
doi = "10.1097/PRS.0b013e3181bf8024",
language = "English (US)",
volume = "124",
pages = "1829--1839",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Scaffold-based rhBMP-2 therapy in a rat alveolar defect model

T2 - Implications for human gingivoperiosteoplasty

AU - Nguyen, Phuong D.

AU - Lin, Clarence D.

AU - Allori, Alexander C.

AU - Schachar, Jeffrey S.

AU - Ricci, John

AU - Saadeh, Pierre B.

AU - Warren, Stephen M.

PY - 2009/12

Y1 - 2009/12

N2 - Background: Primary alveolar cleft repair has a 41 to 73 percent success rate. Patients with persistent alveolar defects require secondary bone grafting. The authors investigated scaffold-based therapies designed to augment the success of alveolar repair. Methods: Critical-size, 7 × 4 × 3-mm alveolar defects were created surgically in 60 Sprague-Dawley rats. Four scaffold treatment arms were tested: absorbable collagen sponge, absorbable collagen sponge plus recombinant human bone morphogenetic protein-2 (rhBMP-2), hydroxyapatite-tricalcium phosphate, hydroxyapatite-tricalcium phosphate plus rhBMP-2, and no scaffold. New bone formation was assessed radiomorphometrically and histomorphometrically at 4, 8, and 12 weeks. Results: Radiomorphometrically, untreated animals formed 43 ± 6 percent, 53 ± 8 percent, and 48 ± 3 percent new bone at 4, 8, and 12 weeks, respectively. Animals treated with absorbable collagen sponge formed 50 ± 6 percent, 79 ± 9 percent, and 69 ± 7 percent new bone, respectively. Absorbable collagen sponge plus rhBMP-2-treated animals formed 49 ± 2 percent, 71 ± 6 percent, and 66 ± 7 percent new bone, respectively. Hydroxyapatite- tricalcium phosphate treatment stimulated 69 ± 12 percent, 86 ± 3 percent (p < 0.05), and 87 ± 14 percent new bone, respectively. Histomorphometry demonstrated an increase in bone formation in animals treated with hydroxyapatite-tricalcium phosphate plus rhBMP-2 (p < 0.05; 4 weeks) compared with empty scaffold. Conclusions: Radiomorphometrically, absorbable collagen sponge and hydroxyapatite-tricalcium phosphate scaffolds induced more bone formation than untreated controls. The rhBMP-2 added a small but significant histomorphometric osteogenic advantage to the hydroxyapatite- tricalcium phosphate scaffold.

AB - Background: Primary alveolar cleft repair has a 41 to 73 percent success rate. Patients with persistent alveolar defects require secondary bone grafting. The authors investigated scaffold-based therapies designed to augment the success of alveolar repair. Methods: Critical-size, 7 × 4 × 3-mm alveolar defects were created surgically in 60 Sprague-Dawley rats. Four scaffold treatment arms were tested: absorbable collagen sponge, absorbable collagen sponge plus recombinant human bone morphogenetic protein-2 (rhBMP-2), hydroxyapatite-tricalcium phosphate, hydroxyapatite-tricalcium phosphate plus rhBMP-2, and no scaffold. New bone formation was assessed radiomorphometrically and histomorphometrically at 4, 8, and 12 weeks. Results: Radiomorphometrically, untreated animals formed 43 ± 6 percent, 53 ± 8 percent, and 48 ± 3 percent new bone at 4, 8, and 12 weeks, respectively. Animals treated with absorbable collagen sponge formed 50 ± 6 percent, 79 ± 9 percent, and 69 ± 7 percent new bone, respectively. Absorbable collagen sponge plus rhBMP-2-treated animals formed 49 ± 2 percent, 71 ± 6 percent, and 66 ± 7 percent new bone, respectively. Hydroxyapatite- tricalcium phosphate treatment stimulated 69 ± 12 percent, 86 ± 3 percent (p < 0.05), and 87 ± 14 percent new bone, respectively. Histomorphometry demonstrated an increase in bone formation in animals treated with hydroxyapatite-tricalcium phosphate plus rhBMP-2 (p < 0.05; 4 weeks) compared with empty scaffold. Conclusions: Radiomorphometrically, absorbable collagen sponge and hydroxyapatite-tricalcium phosphate scaffolds induced more bone formation than untreated controls. The rhBMP-2 added a small but significant histomorphometric osteogenic advantage to the hydroxyapatite- tricalcium phosphate scaffold.

UR - http://www.scopus.com/inward/record.url?scp=74049130958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049130958&partnerID=8YFLogxK

U2 - 10.1097/PRS.0b013e3181bf8024

DO - 10.1097/PRS.0b013e3181bf8024

M3 - Article

C2 - 19952639

AN - SCOPUS:74049130958

VL - 124

SP - 1829

EP - 1839

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 6

ER -